Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jinf.2018.07.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of high doses of intravenous fosfomycin for treatment of urinary tract infection caused by KPC carbapenemase-producing Klebsiella pneumoniae. An observational study.
J Glob Antimicrob Resist
December 2024
Maimonides Biomedical Research Institute of Córdoba (IMIBIC); Microbiology Unit, Reina Sofia University Hospital; Córdoba, Spain; Department of Agricultural Chemistry, Soil Science and Microbiology, University of Cordoba, Cordoba, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Objectives: To evaluate the efficacy of high-dose intravenous fosfomycin for the treatment of urinary tract infections (UTI) caused by KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp). A secondary objective was to evaluate the impact of the results of fosfomycin susceptibility testing on prognosis.
Methods: This is an observational and retrospective study.
Enterococcus avium Infection After Liver Transplantation in Vietnam: A Case Report.
Transplant Proc
December 2024
Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam. Electronic address:
Background: The infectious complications are the most common and can be life-threatening to liver transplant recipients, in particular, within the first month after transplantation. Early diagnosis of these severe complications and accurate detection of causative etiologies are crucial for the choice of therapeutic strategies and management of liver transplants.
Case Report: We present a case report of a patient with a history of primary sclerosing cholangitis who underwent a liver transplantation (LT) from a living donor.
Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods.
Antibiotics (Basel)
November 2024
Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic.
Fosfomycin (FOS) is an older antimicrobial agent newly rediscovered as a possible treatment for infections with limited therapeutic options (e.g., Gram-negative bacteria with difficult-to-treat resistance, DTR), especially in intravenous form.
View Article and Find Full Text PDFIntravenous fosfomycin indications and treatment outcomes in pediatric usage: analysis from a single center in Turkey.
J Trop Pediatr
August 2024
Department of Pediatric Infectious Disease, Ankara Yıldırım Beyazıt University, Ankara Bilkent City Hospital, Ankara 06800, Turkey.
Current data on fosfomycin usage in children are limited. We present data on the clinical use of intravenous (IV) fosfomycin in children. Hospitalized patients who received ≥3 days of IV fosfomycin between April 2021 and March 2023 were analyzed retrospectively.
View Article and Find Full Text PDFCombination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature.
J Antimicrob Chemother
October 2024
Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA.
Article Synopsis
- - Treatment of serious infections caused by resistant Gram-negative bacteria is challenging, prompting the use of combination therapies, particularly with IV fosfomycin.
- - Preclinical and clinical studies show that combining IV fosfomycin with β-lactams, polymyxins, or aminoglycosides can produce effective results, matching or exceeding traditional combinations in effectiveness.
- - Clinical success rates for fosfomycin combinations are comparable to existing treatments, especially in cases of pneumonia or bacteraemia due to resistant strains like Klebsiella pneumoniae and Pseudomonas aeruginosa, suggesting it as a valuable alternative treatment option.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!